<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03314987</url>
  </required_header>
  <id_info>
    <org_study_id>20.0258</org_study_id>
    <secondary_id>5R01ES019217</secondary_id>
    <nct_id>NCT03314987</nct_id>
  </id_info>
  <brief_title>Nucleophilic Defense Against PM Toxicity (NEAT Trial)</brief_title>
  <acronym>NEAT</acronym>
  <official_title>Nucleophilic Defense Against PM Toxicity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Louisville</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Environmental Health Sciences (NIEHS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Louisville</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Carnosine is a naturally occurring peptide found in high levels in skeletal muscle and the&#xD;
      brain and is also available commercially as a dietary supplement. Since carnosine has&#xD;
      anti-oxidant properties and air pollution exposure induces a state of oxidative stress, the&#xD;
      purpose of this study is to see if those taking carnosine as a dietary supplement are&#xD;
      protected from air pollution-induced oxidative stress and adverse cardiovascular outcomes.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a placebo controlled, randomized, double-blind, interventional trial investigating&#xD;
      the efficacy of carnosine in reducing the effects of particulate matter air pollution&#xD;
      (PM2.5). A total of 240 participants from the Louisville metropolitan and neighboring areas&#xD;
      will be randomized into two dietary supplement study groups - carnosine (n=120) versus&#xD;
      placebo (n=120). Intervention of study dietary supplements will occur from May through&#xD;
      September, when the levels of PM2.5.are highest in the Louisville, KY area. Study&#xD;
      participants will be given a daily oral dose of total of 2 grams of carnosine (or placebo)&#xD;
      for a total of 12 consecutive weeks (during May through September).&#xD;
&#xD;
      Urinary levels of carnosine will be used to screen and identify potential candidates with low&#xD;
      carnosine levels. Those with levels less than the median levels of the population, will be&#xD;
      invited to participate in the study. The following measurements will be performed - blood and&#xD;
      urine sample collection, physical examination, arterial stiffness, physical function, and&#xD;
      self-reported surveys on environmental exposure, sleep, diet, and exercise. Supplement&#xD;
      intervention (carnosine or placebo) will be initiated at the time of Baseline Assessment and&#xD;
      will continue for 12 weeks from that date. Two follow up visits will occur at 6 weeks and 12&#xD;
      weeks respectively after initiating supplementation.&#xD;
&#xD;
      This innovative clinical investigation will provide an insight into the pre and post&#xD;
      intervention effects of a cheap, safe, and over-the-counter available dietary supplement in&#xD;
      countering the effects of air pollution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">October 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>placebo controlled, randomized, double-blind</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>double blind (participant, investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>endothelial progenitor cells</measure>
    <time_frame>3 months</time_frame>
    <description>circulating pro-angiogenic cells</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>arterial stiffness</measure>
    <time_frame>3 months</time_frame>
    <description>index of arterial function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>endothelial microparticles</measure>
    <time_frame>3 months</time_frame>
    <description>index of endothelial damage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>platelet monocyte aggregates</measure>
    <time_frame>3 months</time_frame>
    <description>index of platelet activation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Air Pollution Toxicity</condition>
  <arm_group>
    <arm_group_label>intervention group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Each participant will be given a daily oral dose of 2 grams of carnosine for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Each participant will be given a daily oral dose of 2 grams of placebo for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L-carnosine</intervention_name>
    <description>a naturally occurring di-peptide</description>
    <arm_group_label>intervention group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>an identically appearing supplement</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individuals between 22-65 years of age of either gender and all ethnicities,&#xD;
&#xD;
          2. All genders and all ethnicities&#xD;
&#xD;
          3. Residing in or near the Louisville metropolitan area&#xD;
&#xD;
          4. Consumes some type of meat/fish at least once a month during the past 3 months&#xD;
&#xD;
          5. Carnosine levels below the median level of the population&#xD;
&#xD;
          6. Agrees to complete all study visits and follow study intervention regimen&#xD;
&#xD;
          7. Will be living in the study area throughout the study period, with no more than 1 week&#xD;
             away from the study area.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Consumed any dietary supplement more than 3 times per week in the past 4 weeks (one&#xD;
             month)&#xD;
&#xD;
          2. Current / ongoing treatment for substance abuse&#xD;
&#xD;
          3. Currently undergoing treatment or have conditions which may cause participant to be&#xD;
             immunosuppressed&#xD;
&#xD;
          4. Diseases Affecting Peripheral Cell Count (i.e. Autoimmune Diseases - Hashimoto,&#xD;
             Rheumatoid Arthritis, SLE, Rheumatoid Arthritis, Sjogren syndrome, Ankylosing&#xD;
             Spondylitis, Takayasu arteritis, Kawasaki disease, Polyarteritis nodosa.)&#xD;
&#xD;
          5. Diseases Affecting Bone Marrow capacity&#xD;
&#xD;
          6. Diagnosis of any active cancer&#xD;
&#xD;
          7. Recent organ / kidney transplant or replacement (Active/Long-Term Medications)&#xD;
&#xD;
          8. Type 1 Diabetes Mellitus&#xD;
&#xD;
          9. Untreated thyroid disease&#xD;
&#xD;
         10. Untreated anemia&#xD;
&#xD;
         11. Current acute infections (Influenza, fever, etc.)&#xD;
&#xD;
         12. HIV positive status&#xD;
&#xD;
         13. Active/current Hepatitis HepA, HepB or HepC or in past 6 months&#xD;
&#xD;
         14. Currently or planning to be Pregnant / lactating&#xD;
&#xD;
         15. Prisoners / vulnerable populations&#xD;
&#xD;
         16. Other medical conditions that compromise completion of study&#xD;
&#xD;
         17. Unwilling to provide consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Timothy E O'Toole, Ph.D.</last_name>
    <phone>502-852-5886</phone>
    <email>teotoo01@louisville.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alok Amraotkar, M.D.</last_name>
    <phone>502-852-7559</phone>
    <email>alok.amraotkar@louisville.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Trials Unit</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Caswell</last_name>
      <phone>502-587-4177</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>O'Toole TE, Hellmann J, Wheat L, Haberzettl P, Lee J, Conklin DJ, Bhatnagar A, Pope CA 3rd. Episodic exposure to fine particulate air pollution decreases circulating levels of endothelial progenitor cells. Circ Res. 2010 Jul 23;107(2):200-3. doi: 10.1161/CIRCRESAHA.110.222679. Epub 2010 Jul 1.</citation>
    <PMID>20595651</PMID>
  </reference>
  <results_reference>
    <citation>Barski OA, Xie Z, Baba SP, Sithu SD, Agarwal A, Cai J, Bhatnagar A, Srivastava S. Dietary carnosine prevents early atherosclerotic lesion formation in apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol. 2013 Jun;33(6):1162-70. doi: 10.1161/ATVBAHA.112.300572. Epub 2013 Apr 4.</citation>
    <PMID>23559625</PMID>
  </results_reference>
  <results_reference>
    <citation>Pope CA 3rd, Bhatnagar A, McCracken JP, Abplanalp W, Conklin DJ, O'Toole T. Exposure to Fine Particulate Air Pollution Is Associated With Endothelial Injury and Systemic Inflammation. Circ Res. 2016 Nov 11;119(11):1204-1214. doi: 10.1161/CIRCRESAHA.116.309279. Epub 2016 Oct 25.</citation>
    <PMID>27780829</PMID>
  </results_reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 16, 2017</study_first_submitted>
  <study_first_submitted_qc>October 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Louisville</investigator_affiliation>
    <investigator_full_name>Timothy Edward O'Toole</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>air pollution</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>intervention</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

